Clinical trials: Colorectal Cancer Metastatic
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
This 2 arm study will compare the pharmacokinetics and safety of Avastin at steady state under 2 different dosing regimens, in combination with XELOX (oxaliplatin + Xeloda) or FOLFOX-4 (oxaliplatin, leucovorin and…
- Trial name
- NCT00349336
- Testing
- bevacizumab [Avastin], XELOX, FOLFOX-4
- Where
- 7 sites in Australia, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- Hoffmann-La Roche
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
This is an open-label, prospective, randomized, multicenter phase II trial that will evaluate the efficacy and safety of intermittent addition of cetuximab to a FOLFIRI-based first line therapy to patients with RAS (Rat…
- Trial name
- NCT04554836
- Testing
- Cetuximab, FOLFIRI
- Where
- 4 sites in Germany
- Volunteers
- 6 people
- Sponsor
- TheraOp
Metastatic Colorectal Cancer
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
This study will compare the safety and efficacy of dalotuzumab (MK-0646) in combination with cetuximab and irinotecan in treating participants with wild type KRAS (wtKRAS) metastatic colorectal cancer (CRC) compared to cetuximab…
- Trial name
- NCT00614393
- Testing
- dalotuzumab, irinotecan hydrochloride, cetuximab
- Volunteers
- 558 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Regorafenib is approved in the treatment for metastatic colorectal cancer patients who have been progressed after standard therapies, however, there has not been a predictive biomarker.
- Trial name
- NCT02175095
- Testing
- Regorafenib, [18F]FLT-PET, [18F]FDG-PET
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Asan Medical Center
Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
This phase II trial studies how well capecitabine and celecoxib with or without radiation therapy works in treating patients with colorectal cancer that is newly diagnosed or has been previously treated with fluorouracil, and has…
- Conditions
- Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
- Trial name
- ADAPT (NCT01729923)
- Testing
- Capecitabine, Celecoxib, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
Colorectal Cancer
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
People with colorectal cancer that cannot be cured by surgery are being asked to participate in this study. The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and temozolomide…
- Trial name
- NCT01051596
- Testing
- Temozolomide, ABT-888
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Georgetown University
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Cancer of the Colon, Colon Cancer
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
This research study is designed to provide a better understanding of study drugs cetuximab (Erbitux®) and palbociclib when used in combination to treat patients with metastatic colon cancer.
- Conditions
- Cancer of the Colon, Colon Cancer, Colon Neoplasms, Colonic Cancer
- Trial name
- NCT03446157
- Testing
- Cetuximab, Palbociclib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
This phase II trial studies how well panitumumab and combination chemotherapy works in treating patients with metastatic colorectal cancer previously treated with combination chemotherapy and bevacizumab.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT01814501
- Testing
- panitumumab, irinotecan hydrochloride, fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- John Hays
Rectal Neoplasms
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)
The purpose of this adaptive trial is to compare the progression-free survival of participants with metastatic rectal carcinoma when treated with intravenous (IV) dalotuzumab (MK-0646) + irinotecan therapy relative to…
- Trial name
- NCT01609231
- Testing
- Dalotuzumab, Irinotecan, Cetuximab
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Approximately 36 DLT-evaluable subjects will be enrolled in this study. The locations of the study will be in the United States, Australia, Europe and Switzerland.
- Trial name
- NCT03256344
- Testing
- Talimogene Laherparepvec, Atezolizumab
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 36 people
- Sponsor
- Amgen
Neoplasms
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: has spread to other parts of the…
- Trial name
- NCT04607421
- Testing
- Encorafenib, Cetuximab, Oxaliplatin
- Where
- 274 sites in United States, Argentina and 27 more
- Volunteers
- 841 people
- Sponsor
- Pfizer
Metastatic Colorectal Adenocarcinoma
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
The purpose of this study is to evaluate the good and bad effects when regorafenib is used instead of standard combination chemotherapy.
- Trial name
- NCT02023333
- Testing
- Regorafenib
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Neoplasms
Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and efficacy of Abraxane (nab-paclitaxel) in subjects with previously treated metastatic colorectal cancer.
- Trial name
- NCT02103062
- Testing
- ABI-007
- Where
- 6 sites in France
- Volunteers
- 41 people
- Sponsor
- Celgene
Colon Cancer, Colorectal Cancer
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
This study is a global, multicenter, open-label phase 1b and randomized, double-blinded, 2 part, phase 2 study designed to evaluate the safety and efficacy of rilotumumab or ganitumab in combination with panitumumab versus…
- Conditions
- Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT00788957
- Testing
- Panitumumab, Ganitumab, Rilotumumab
- Volunteers
- 177 people
- Sponsor
- NantBioScience, Inc.
Colorectal Neoplasms
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
The objective of this Phase II study is to assess the efficacy and safety of nintedanib alone or in combination with capecitabine for patients with refractory metastatic colorectal cancer (mCRC) after failure of at least 2 lines…
- Trial name
- NCT02780700
- Testing
- Nintedanib, Capecitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer
This 2 arm study assessed the efficacy and safety of maintenance treatment with Avastin (bevacizumab) + Xeloda (capecitabine), after initial treatment with Xeloda + oxaliplatin + Avastin, in patients with metastatic colorectal…
- Trial name
- NCT00623805
- Testing
- Bevacizumab, Capecitabine, Oxaliplatin
- Where
- 10 sites in Turkey (Türkiye)
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
FC-6 is a Phase II, multi-center clinical trial for patients with unresectable, wild-type K-RAS, colorectal cancer with metastases confined to the liver.
- Trial name
- NCT00803647
- Testing
- cetuximab, 5-FU, oxaliplatin
- Where
- 23 sites in United States
- Volunteers
- 20 people
- Sponsor
- NSABP Foundation Inc
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
This single arm study will investigate possible pharmacokinetic interactions between Xeloda and oxaliplatin, and assess whether the pharmacokinetics of Xeloda and/or oxaliplatin is influenced by the addition of Avastin.
- Trial name
- NCT00353262
- Testing
- Avastin, Oxaliplatin, capecitabine [Xeloda]
- Where
- 3 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
The purpose of this study is to find out how effective this combination is as a second line treatment for colorectal cancer that has spread from one part of the body to another (metastasized) or has not metastasized but is…
- Trial name
- NCT00574171
- Testing
- lapatinib, Capecitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Wisconsin, Madison